EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 38 / Numéro 11 (Novembre 2022) Med Sci (Paris), 38 11 (2022) 905-912 Références
Genre
Accès gratuit
Numéro
Med Sci (Paris)
Volume 38, Numéro 11, Novembre 2022
Genre
Page(s) 905 - 912
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2022151
Publié en ligne 30 novembre 2022
  1. Standards de soins. World Professional Association for Transgender Health. https://www.wpath.org/media/cms/Documents/SOC%20v7/SOC%20V7_French.pdf. [Google Scholar]
  2. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017 ; 102 : 3869–3903. [CrossRef] [PubMed] [Google Scholar]
  3. Scheres LJJ, Selier NLD, Nota NM, et al. Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen. J Thromb Haemost 2021; 19 : 1029–37. [CrossRef] [PubMed] [Google Scholar]
  4. Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011 ; 164 : 635–642. [CrossRef] [PubMed] [Google Scholar]
  5. LaVasseur C, Neukam S, Kartika T, et al. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res Pract Thromb Haemost 2022; 6 : e12763. [CrossRef] [PubMed] [Google Scholar]
  6. Turino Miranda K, Kalenga CZ, Saad N, et al. Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis. Am J Physiol Heart Circ Physiol 2022 Sep 2. doi: 10.1152/ajpheart.00299.2022. [PubMed] [Google Scholar]
  7. Iwamoto SJ, Defreyne J, Rothman MS, et al. Health considerations for transgender women and remaining unknowns: a narrative review. Ther Adv Endocrinol Metab 2019 ; 10 : 2042018819871166. [CrossRef] [Google Scholar]
  8. Glintborg D, T’Sjoen G, Ravn P, Andersen MS. Management of endocrine disease: Optimal feminizing hormone treatment in transgender people. Eur J Endocrinol 2021; 185 : R49–R63. [CrossRef] [PubMed] [Google Scholar]
  9. https://ansm.sante.fr/actualites/androcur-acetate-de-cyproterone-et-generiques-risque-de-meningiome-lors-dune-utilisation-prolongee. [Google Scholar]
  10. Burinkul S, Panyakhamlerd K, Suwan A, et al. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial. J Sex Med 2021; 18 : 1299–307. [CrossRef] [Google Scholar]
  11. Irwig MS. Is there a role for 5’-reductase inhibitors in transgender individuals? Andrology 2021; 9 : 1729–31. [CrossRef] [PubMed] [Google Scholar]
  12. Patel KT, Adeel S, Miragaya JR, Tangpricha V. Progestogen Use in Gender Affirming Hormone Therapy: A Systematic Review. Endocr Pract 2022 : S1530–891X(22)00600–0. [Google Scholar]
  13. Iwamoto SJ, T’Sjoen G, Safer JD, et al. Letter to the Editor: “Progesterone Is Important for Transgender Women’s Therapy-Applying Evidence for the Benefits of Progesterone in Ciswomen”. J Clin Endocrinol Metab 2019 ; 104 : 3127–3128. [CrossRef] [PubMed] [Google Scholar]
  14. Nolan BJ, Frydman AS, Leemaqz SY, et al. Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study. Endocr Connect 2022; 11 : e220170. [CrossRef] [PubMed] [Google Scholar]
  15. de Blok CJM, Dijkman BAM, Wiepjes CM, et al. Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment. J Clin Endocrinol Metab 2021; 106 : e782–90. [CrossRef] [PubMed] [Google Scholar]
  16. Klaver M, de Blok CJM, Wiepjes CM, et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study. Eur J Endocrinol 2018 ; 178 : 163–171. [CrossRef] [PubMed] [Google Scholar]
  17. Van Caenegem E, Taes Y, Wierckx K, et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone 2013 ; 54 : 92–97. [CrossRef] [PubMed] [Google Scholar]
  18. Verroken C, Collet S, Lapauw B, T’Sjoen G. Osteoporosis and Bone Health in Transgender Individuals. Calcif Tissue Int 2022; 110 : 615–23. [CrossRef] [PubMed] [Google Scholar]
  19. Getahun D, Nash R, Flanders WD, et al. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study. Ann Intern Med 2018 ; 169 : 205–213. [CrossRef] [PubMed] [Google Scholar]
  20. Streed CG, Jr, Harfouch O, Marvel F, et al. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann Intern Med 2017 ; 167 : 256–267. [CrossRef] [PubMed] [Google Scholar]
  21. Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2017 ; 102 : 3914–3923. [CrossRef] [PubMed] [Google Scholar]
  22. Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy. Circulation 2019 ; 139 : 1461–1462. [CrossRef] [PubMed] [Google Scholar]
  23. Totaro M, Palazzi S, Castellini C, et al. Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study. Front Endocrinol (Lausanne) 2021; 12 : 741866. [CrossRef] [PubMed] [Google Scholar]
  24. Cocchetti C, Castellini G, Iacuaniello D, et al. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). J Sex Med 2021; 18 : 821–9. [CrossRef] [PubMed] [Google Scholar]
  25. van Velzen DM, Adorni MP, Zimetti F, et al. The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity. Atherosclerosis 2021; 323 : 44–53. [CrossRef] [PubMed] [Google Scholar]
  26. Islam N, Nash R, Zhang Q, et al. Is There a Link Between Hormone Use and Diabetes Incidence in Transgender People? Data From the STRONG Cohort. J Clin Endocrinol Metab 2022; 107 : e1549–57. [CrossRef] [PubMed] [Google Scholar]
  27. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019; 365 : l1652. [CrossRef] [PubMed] [Google Scholar]
  28. Baraban E, Ding CC, White M, et al. Prostate Cancer in Male-to-Female Transgender Individuals: Histopathologic Findings and Association With Gender-affirming Hormonal Therapy. Am J Surg Pathol 2022 Aug 26. doi: 10.1097/PAS.0000000000001964. [PubMed] [Google Scholar]
  29. Cocchetti C, Romani A, Collet S, et al. The ENIGI (European Network for the Investigation of Gender Incongruence) Study: Overview of Acquired Endocrine Knowledge and Future Perspectives. J Clin Med 2022; 11 : 1784. [CrossRef] [PubMed] [Google Scholar]
  30. Taub RL, Ellis SA, Neal-Perry G, et al. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol 2020; 223 : 229.e1-8. [CrossRef] [PubMed] [Google Scholar]
  31. Mancini I, Alvisi S, Gava G, et al. Contraception across transgender. Int J Impot Res 2020; 33 : 710–9. [Google Scholar]
  32. Baker KE, Wilson LM, Sharma R, et al. Hormone Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review. J Endocr Soc 2021; 5 : bvab011. [CrossRef] [PubMed] [Google Scholar]
  33. Bultynck C, Pas C, Defreyne J, et al. Self-perception of voice in transgender persons during cross-sex hormone therapy. Laryngoscope 2017 ; 127 : 2796–2804. [CrossRef] [PubMed] [Google Scholar]
  34. Irwig MS, Childs K, Hancock ABEffects of testosterone on the transgender male voice. Andrology 2017 ; 5 : 107–112. [CrossRef] [PubMed] [Google Scholar]
  35. Scharff M, Wiepjes CM, Klaver M, et al. Change in grip strength in trans people and its association with lean body mass and bone density. Endocr Connect 2019 ; 8 : 1020–1028. [CrossRef] [PubMed] [Google Scholar]
  36. Vita R, Settineri S, Liotta M, et al. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study. Maturitas 2018 ; 107 : 92–96. [CrossRef] [PubMed] [Google Scholar]
  37. Tebbens M, Nota NM, Liberton NPTJ, et al. Gender-Affirming Hormone Treatment Induces Facial Feminization in Transwomen and Masculinization in Transmen: Quantification by 3D Scanning and Patient-Reported Outcome Measures. J Sex Med 2019 ; 16 : 746–754. [CrossRef] [PubMed] [Google Scholar]
  38. Wiepjes CM, den Heijer M, T’Sjoen GGBone health in adult trans persons: an update of the literature. Curr Opin Endocrinol Diabetes Obes 2019 ; 26 : 296–300. [CrossRef] [PubMed] [Google Scholar]
  39. Wiepjes CM, Vlot MC, Klaver M, et al. Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment: A Multicenter Prospective Observational Study. J Bone Miner Res 2017 ; 32 : 1252–1260. [CrossRef] [PubMed] [Google Scholar]
  40. Pirtea P, Ayoubi JM, Desmedt S, T’Sjoen G. Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men. Fertil Steril 2021; 116 : 936–42. [CrossRef] [PubMed] [Google Scholar]
  41. Madsen MC, van Dijk D, Wiepjes CM, et al. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years. J Clin Endocrinol Metab 2021; 106 : 1710–7. [CrossRef] [PubMed] [Google Scholar]
  42. Defreyne J, Vantomme B, Van Caenegem E, et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. Andrology 2018 ; 6 : 446–454. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.